BACKGROUND: Serotonin reuptake inhibitor (SRI) medications are commonly in use during pregnancy. OBJECTIVES: To evaluate short-term neonatal clinical signs among infants exposed to intrauterine SRI medications, in order to estimate the need for postnatal monitoring and observation. METHODS: Retrospective review of clinical data in medical files of term infants born to mothers who reported treatment with SRIs during pregnancy. RESULTS: Out of 401 infants in the study group, 165 (41%) were reported to have at least 1 clinical symptom, including respiratory distress, jitteriness, restlessness, feeding difficulties, regurgitations, fever ≥38°C, a short cyanotic event and convulsions. In the symptomatic group, 70% exhibited mild symptoms, among them restlessness, jitteriness or feeding difficulties, while around 30% exhibited significant symptoms. Overall, 12% of the total cohort, mostly males (70%), presented significant clinical symptoms, but none had an urgent or life-threatening condition. Infants in the study group were shorter in length and had a higher rate of Apgar score <7 at 1 min, meconium-stained amniotic fluid and respiratory distress. CONCLUSIONS: Despite the high incidence of clinical signs among infants born to SRI-treated mothers, most of their symptoms were mild and self-limited. These infants should be observed while they are close to their mothers on the maternity ward for 48 h after birth.
BACKGROUND: Serotonin reuptake inhibitor (SRI) medications are commonly in use during pregnancy. OBJECTIVES: To evaluate short-term neonatal clinical signs among infants exposed to intrauterine SRI medications, in order to estimate the need for postnatal monitoring and observation. METHODS: Retrospective review of clinical data in medical files of term infants born to mothers who reported treatment with SRIs during pregnancy. RESULTS: Out of 401 infants in the study group, 165 (41%) were reported to have at least 1 clinical symptom, including respiratory distress, jitteriness, restlessness, feeding difficulties, regurgitations, fever ≥38°C, a short cyanotic event and convulsions. In the symptomatic group, 70% exhibited mild symptoms, among them restlessness, jitteriness or feeding difficulties, while around 30% exhibited significant symptoms. Overall, 12% of the total cohort, mostly males (70%), presented significant clinical symptoms, but none had an urgent or life-threatening condition. Infants in the study group were shorter in length and had a higher rate of Apgar score <7 at 1 min, meconium-stained amniotic fluid and respiratory distress. CONCLUSIONS: Despite the high incidence of clinical signs among infants born to SRI-treated mothers, most of their symptoms were mild and self-limited. These infants should be observed while they are close to their mothers on the maternity ward for 48 h after birth.
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Holly J Engelstad; Robert D Roghair; Chadi A Calarge; Tarah T Colaizy; Scott Stuart; Sarah E Haskell Journal: Neonatology Date: 2013-12-18 Impact factor: 4.035
Authors: Kelsey Kathleen Wiggs; Ayehsa C Sujan; Martin E Rickert; Patrick D Quinn; Henrik Larsson; Paul Lichtenstein; Brian M D'Onofrio; A Sara Oberg Journal: Neurology Date: 2022-05-11 Impact factor: 11.800